[Splenic marginal zone B cell lymphomas].

Der Pathologe
M M Ott, H K Müller-Hermelink

Abstract

Splenic marginal zone B cell lymphomas (SMZBCL) are rare, organotypic, lymphoid neoplasms with distinct clinicopathological features. At initial presentation, the spleen, bone marrow and peripheral blood are usually involved, while generalized lymphadenopathy is only rarely observed. Molecularly, somatic hypermutation of IgVH genes can be detected in roughly half of the cases, and deletions in 7q are present in 45% of tumors. Approximately 10%-15% of SMZBCL do occur in the setting of chronic hepatitis C. This association underlines the importance of antigenic stimulation in the proliferation of the tumor cells in HCV-associated SMBCL, if not also in their classical counterparts. More recently, gene profiling studies using cDNA microarrays revealed a homogeneous expression profile in SMZBCL, thus further confirming the notion of a distinct tumor entity. The clinical course is indolent in the majority of cases; however, some patients follow a more aggressive clinical course, usually associated with some particular molecular features in these tumors, such as unmutated IgVH genes and 7q deletions.

References

May 1, 1992·The American Journal of Surgical Pathology·C SchmidP G Isaacson
Dec 1, 1989·Human Pathology·J J van den OordV J Desmet
Jul 1, 1997·The American Journal of Surgical Pathology·M MollejoP G Isaacson
Sep 24, 1998·Immunology Today·J SpencerD K Dunn-Walters
May 18, 1999·The American Journal of Pathology·M MateoM A Piris
Jun 22, 2000·Genes, Chromosomes & Cancer·M M OttH K Müller-Hermelink
Jul 12, 2002·The New England Journal of Medicine·Olivier HermineXavier Troussard
Feb 17, 2006·European Journal of Haematology·Achille PichGiorgio Palestro
Feb 24, 2006·Blood·Luca ArcainiUNKNOWN Integruppo Italiano Linfomi

❮ Previous
Next ❯

Citations

Aug 26, 2009·World Journal of Gastroenterology : WJG·Rajko MilosevicBiljana Mihaljevic

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.